HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

A randomized,multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated AML as shown with overall survival compared to salvage chemotherapy, and also to investigate the efficacy of Clifutinib as assessed by CR/CRh rate in these subjects.

Trial Details

NCT ID
NCT05586074
Phase
PHASE3
Sponsor
Sunshine Lake Pharma Co., Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Clifutinib
  • LoDAC
  • Azacitidine
  • Decitabine
  • Ara-C±IDA
  • FLAG-IDA
Locations (sample)
  • Hanzhou, China|26.4965,99.437

Key Eligibility Criteria

  • Subject is ≥ 18 years of age at the time of obtaining informed consent.
  • Subject has a diagnosis of primary acute myeloid leukemia (AML) or AML secondary to myelodysplastic syndrome (MDS) according to WHO classification;
  • Subject is refractory to or relapsed after first-line AML therapy (with or without hematopoietic stem cell transplant )
  • Subject is positive for FLT3 mutation in bone marrow or whole blood as determined by the central lab

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →